Robin Adelstein

Global Head of Antitrust and Competition Norton Rose Fulbright US LLP

New York +1 212 318 3108

Washington, DC +1 202 662 0200

New York +1 212 318 3108

Washington, DC +1 202 662 0200

vCard

Robin Adelstein

Robin Adelstein is Norton Rose Fulbright's Global Head of Antitrust and Competition and US Co-Head of Commercial Litigation.

Robin's pragmatic approach to the practice of law is informed by her experience, having served as in-house antitrust and litigation counsel at Swiss healthcare company Novartis and UK alcohol beverage leader Diageo before becoming North American General Counsel of Sandoz, the generics and biosimilars division of Novartis.

Whether involving pharmaceuticals, consumer products or other industries, Robin has advised her clients on a wide variety of issues and directed material litigation and government investigations to positive results. As a former General Counsel of a multibillion-dollar company, Robin knows first-hand the importance of providing prompt, accurate and practical advice on legal and compliance issues, particularly in the context of balancing complex business objectives. Robin also understands the challenges with managing outside counsel, having redesigned and run the Novartis Preferred Firm Program globally.

Robin litigates complex, commercial disputes, class actions and multi-jurisdictional cases before US federal and state courts, and represents clients in government enforcement actions by the U.S. Federal Trade Commission and U.S. Department of Justice, as well as the HHS Office of the Inspector General. She has defended clients in qui tam matters in many locales and in investigations and litigation by numerous State Attorneys General. Robin also advises companies with respect to the antitrust issues arising in mergers and acquisitions, joint ventures, trade association activities, distribution practices, pricing programs and other aspects of competitor and customer communications and associations.

Professional experience

Representative experience

Noteworthy representations have included the following:

Representing global pharmaceutical company in putative antitrust class action consolidated in multidistrict litigation in the United States District Court for the Eastern District of Pennsylvania. The plaintiffs allege that generic drug manufacturers have colluded to fix, stabilize and raise prices and allocate markets of generic drugs purportedly in violation of the Sherman Act and state antitrust and other laws.
Representing alcohol beverage distributor in antitrust litigation pending in the United States District Court for the Northern District of Illinois alleging that the distributor, along with its competitor, conspired to restrain trade and monopolized or attempted to monopolize various markets for online distribution of wine and spirits in violation of the Sherman Act and state antitrust and other laws.
Representing global pharmaceutical company in litigation pending in the United States District Court for the Southern District of New York alleging breach of a supply agreement for the purchase of active pharmaceutical ingredient.
Representing plaintiffs manufacturer and distributor of generic pharmaceutical product in litigation pending in the District of New Jersey brought against a pharmaceutical company and active pharmaceutical ingredient supplier alleging monopolization and an unlawful agreement to restrict the sale of API to plaintiffs in violation of the Sherman Act and state antitrust and other laws.
Represented global life sciences company in litigation pending in New York State Supreme Court alleging breach of contract and fraud claims relating to the purchase of a medical diagnostic and testing equipment business.
Represented alcohol beverage distributor in antitrust litigation pending in the United States District Court for the Northern District of Oklahoma alleging a per se group boycott, monopolization and attempted monopolization in violation of the Sherman Act. Successfully settled case following partial win on motion to dismiss.
Retained as mediator by alcohol beverage supplier and distributor in connection with on-going American Arbitration Association arbitration over breach of contract dispute relating to distribution of spirits products.
Represented global pharmaceutical company in ICC arbitration for breach of a license and commercialization agreement based on respondent's failure to use commercially reasonable efforts to commercialize the pharmaceutical product. Obtained complete award, including damages, termination of the license agreement, and an injunction requiring return of the pharmaceutical product.
Represented pharmaceutical manufacturer in successful dismissal of antitrust litigation in the United States District Court for the Eastern District of Pennsylvania alleging violations of the Sherman Act and state antitrust laws. The plaintiff claimed that defendants allegedly maintained an unlawful monopoly over an orphan drug by preventing plaintiff from acquiring samples in order to manufacture a generic equivalent.
Represented disposable contact lens manufacturer in putative antitrust class actions consolidated in multidistrict litigation in the United States District Court for the Middle District of Florida. The plaintiffs alleged horizontal price fixing among contact lens manufacturers and vertical resale price maintenance purportedly in violation of the Sherman Act and state antitrust laws.
Represented pharmaceutical company in its Medicaid pricing fraud litigation brought by state attorneys general and a federal qui tam relator. Successfully obtained reversals by the Alabama Supreme Court overturning a multimillion-dollar jury verdict and by the Kentucky Court of Appeals overturning a multimillion-dollar jury verdict.
Represented global companies and individuals in breach of contract and securities fraud litigation brought by representative of former shareholders of acquired entity. Successfully obtained dismissal on constitutional standing grounds of securities fraud claims and pendent state law claims.
Represented global company in securities litigation challenging a multibillion-billion acquisition. Successfully obtained dismissal on forum non conveniens grounds of putative class action litigation.
Represented global company in derivative litigation against it and current and former officers and directors. Successfully obtained dismissal on the basis that plaintiff lacked standing under Swiss law to bring a derivative suit and that even if the plaintiff did have standing it would be subject to dismissal on forum non conveniens grounds.
Represented pharmaceutical company in putative class action litigation challenging the settlement of patent litigation on antitrust grounds, so-called "reverse payment settlement" cases.
Represented pharmaceutical company in settlement of investigation by the Office of the Inspector General into drug price reporting to the Medicare program.
Represented global company in successfully resolving multibillion-dollar confidential arbitration.
Represented alcohol beverage company in litigation challenging a contractual change of control provision which allegedly arose as a result of a merger.
Represented alcohol beverage company in distributor termination litigation.
Represented alcohol beverage company in successfully obtaining dismissal of a class action litigation alleging that the alcohol beverage industry marketing targeted underage consumers.
Advised alcohol beverage companies on issues relating to their marketing and promotional programs and crafted alcohol beverage social responsibility programs.
Led team responsible for overseeing North American legal aspects of very successful major spirits and wine company acquisition, including managing integration activities.

Rankings and recognitions

"Women in Antitrust," Global Competition Review, 2025, 2021
Lawdragon 500 Leading Litigators in America, Lawdragon, Inc., 2025
Lawdragon 500 Leading Lawyers in America, Lawdragon, Inc., 2024 – 2025
Lawdragon 500 Leading Global Litigators, Lawdragon, Inc., 2023 – 2024
The Best Lawyers in America, Litigation - Antitrust, Best Lawyers, 2022 – 2025
The Best Lawyers in America, Antitrust Law, Best Lawyers, 2021 – 2025
New York Metro Super Lawyer, Antitrust Litigation, Thomson Reuters, 2020 – 2024
"Notable Women in Law," Crain's New York Business, Crain Communications Inc., 2019, 2022
"Notable Diverse Leaders in Law," Crain's New York Business, Crain Communications Inc., 2022
Legal 500 US, Recommended Lawyer, Antitrust - Civil litigation/class actions, The Legal 500, 2016, 2018 – 2024
Legal 500 US, Recommended Lawyer, Dispute resolution - General commercial disputes, The Legal 500, 2023 – 2024
Legal 500 US, Recommended Lawyer, Healthcare - life sciences, The Legal 500, 2016, 2019, 2023
Legal 500 US, Recommended Lawyer, Antitrust - Merger control, The Legal 500, 2019 – 2022
Legal 500 US, Recommended Lawyer, International Litigation, The Legal 500, 2022
Distinguished Leader, New York Law Journal, 2020 (Link to Q&A - subscription required)
BTI Client Service All-Star, The BTI Consulting Group, Inc., 2020

Education

JD, New York University School of Law
AB, magna cum laude, Economics (with honors) and Political Science, Colgate University, Phi Beta Kappa

Robin is admitted to practice in the State of New York, District of Columbia, United States Supreme Court, United States Courts of Appeal for the Second, Third, Eleventh and Federal Circuits, United States Court of Federal Claims and United States District Court for the Southern District of New York.

Admissions

District of Columbia Bar
New York State Bar

Publications

Quoted in, "The Legal Work Awaiting Attys During Trump's Second Term," Law360, November 6, 2024
Quoted in, "Biden's Bid to Reshape Competition Law Thwarted by Trump Win," Bloomberg Law, November 6, 2024
Quoted in, "Tech leaders brace for high-stakes election," CFO Drive, October 29, 2024
Co-author, "How Biden Admin Has Used Antitrust Tools, And What's Next," Law360, October 11, 2024
Contributor, "The Election: How each candidate is likely to affect the future of M&A," The M&A Journal, October 8, 2024
Quoted in, "The Antitrust Agenda: Experts Discuss Potential Top Roles in a Harris Administration," The Capitol Forum, October 7, 2024
Quoted in, “Trump, Harris Might Alter DOJ, FTC Enforcement in Counterintuitive Ways,” Corporate Counsel, September 30, 2024
Co-author, "FTC’s near-total ban on noncompete agreements challenged," Norton Rose Fulbright Legal Update, April 23, 2024
Co-author, "Antitrust Enforcers' Views On Info Exchanges Are Evolving," Law360, March 15, 2024
Co-author, "New Barriers to Pharma Deals: FTC Challenges Amgen / Horizon Merger Without Alleging Product Overlaps," Norton Rose Fulbright Legal Update, May 25, 2023
Quoted in, "'Change Is The Only Constant': In-House M&A Lessons," Law360 Pulse, April 5, 2023
Co-author, "Section 8 Enforcement," Norton Rose Fulbright Legal Update, March 24, 2023
Quoted in, "Juries Not Buying DOJ Antitrust Labor Push As Losses Mount," Law360, March 23, 2023
Quoted in, "Antitrust Conduct Issues and Cases to Watch in 2023," Law360, January 2, 2023
Quoted in, "Biggest Developments in Antitrust Conduct Cases in 2022,"Law360, December 21, 2022
Quoted in, "Biden Administration's Antitrust Campaign a Concern for Pharma," Drug Discovery & Development, December 15, 2022
Quoted in, "Enforcers' Antitrust Overhaul Just Getting Started," Law360, August 31, 2022
Co-author, "Antitrust in the Biden Administration: Will the new executive order change America?," Norton Rose Fulbright Legal Update, July 15, 2021
Co-author, "US: Settling Class Actions," The Settlements Guide, Global Competition Review Insight, 2021
Co-author, "The New US Antitrust Administration: What's Old is New Again," Concurrences N^o 1, 2021
Co-author, "Enhancing the 'Carrot': A Practical Perspective on DOJ Credit For Antitrust Compliance," Competition Policy International, November 21, 2019
Co-author, "California's legislature passes bill enhancing antitrust scrutiny of patent settlements," Norton Rose Fulbright Legal Update, October 31, 2019. This was also circulated on International Law Office.
Co-author, "Enhancing the 'carrot': DOJ announces changes to its antitrust compliance program policy," Norton Rose Fulbright Legal Update, July 2019. This was also circulated on International Law Office.
Co-author, "FBI and ACCC commit to sharing antitrust enforcement expertise," Norton Rose Fulbright Legal Update, April 2019. This was also circulated on International Law Office.
Co-author, "The FTC eyes settlement agreements that restrict rivals' online search terms," Norton Rose Fulbright Legal Update, November 27, 2018. This was also circulated on International Law Office.
Co-author, "How Pharma Cos. Can Shape The Drug-Pricing Landscape," Law360, Oct. 25, 2016
Quoted in, "Making The Move In-House? Avoid These Rookie Mistakes," Law360, June 20, 2016
Co-author, "Key Securities Litigation Issues For Life Science Cos.," Law360, March 1, 2016
Corporate Counsel Interview, Global Competition Review, Vol. 13 Issue 5, May 2010
Author, "Pre-merger Gun Jumping and Information Exchanges: An In-House Counsel Perspective," ABA Antitrust Section, Corporate Counseling Report, Spring 2002
Member, Editorial Board, ABA Antitrust Section, Antitrust Law Developments, 4th ed. 1997
Vice Chair & Co-Author, ABA Antitrust Section, Monograph No. 22, Predatory Pricing, 1996

Speaking engagements

Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: Litigation lens, November 2023
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: Quick take | Updates to merger guidelines, August 2023
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: US and Canada Antitrust enforcement in labor and employment practices, June 2023
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: International Cartel Investigations, November 2022
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: The impact of the Digital Markets Act, June 2022
Moderator, ABA Section of Antitrust Law Conference, Next Generation of Antitrust, Data Privacy and Data Protection Scholars, "Antitrust Digital Markets," January 2022
Presenter, New York State Bar Association Antitrust Law Section Annual Meeting, "Developments in Pharma Antitrust: Evolution or Revolution?," January 2022
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: Dominance and monopolization investigations, November 2021
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: Antitrust and labor issues, June 2021
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: Quick Take, May 2021
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: The European Commission's once-in-a-decade review of EU rules on vertical agreements and how these changes impact business, February 2021
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: Recent developments in antitrust prosecutions of no-poach and wage fixing agreements related to labor practices in Canada and the US, December 2020
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: Global Class Actions, August 2020
Moderator, Norton Rose Fulbright On-demand Webinar Series | Competitive edge: Developments in global merger control and foreign direct investment review, July 2020
Moderator, Panel Discussion: New York State Bar Antitrust Law Section Webinar: "Should we change our approach to single-firm behavior? Three U.S. Senators think so," May 2020
Moderator, Norton Rose Fulbright Webinar, "Around the world in 60 minutes: a global perspective on COVID-19's impact on antitrust and competition law," April 2020
Interviewee, Women in the Law on the Record Podcast: Interviewed as part of a series of interview-based podcasts spotlighting women in all stages of their legal careers across the country. Listen to the Women in Law podcast aired on January 2020
Guest Lecturer, New York University Stern School of Business, Public Policy and Business Strategy, "Complying with U.S. Antitrust Laws," November 2019
Presenter, Norton Rose Fulbright US LLP Women's Life Sciences Summit, Panel Discussion, "Hot Topics in Life Sciences Antitrust," October 2019
Moderator, Norton Rose Fulbright US LLP 2^nd Annual Silicon Valley International Legal Conference, "Regulatory Investigations," October 2019
Moderator, Norton Rose Fulbright US LLP Roundtable Discussion, "Hipster Antitrust – What's All the Hoopla About?", November 2018
Presenter, Lexis/Nexis National Webinar, "Blockchain and Algorithms: Antitrust in the Digital Age," November 2018
Presenter, Norton Rose Fulbright US LLP Women's Life Sciences Summit, Panel Discussion, "Breaking the Cycle of Underrepresentation at the Highest Levels," October 2018
Moderator, Norton Rose Fulbright US LLP Roundtable Discussion, "Psychology of the Rogue Employee," November 2017
Presenter, Norton Rose Fulbright LLP UK & European Life Sciences Academy, Panel Discussion, "Competition and Pricing Issues," November 2017
Presenter, Norton Rose Fulbright US LLP Women's Life Sciences Summit, Panel Discussion, "Pharma and Antitrust: Trends and Hot Topics," October 2017
Moderator, Norton Rose Fulbright US LLP Women's Life Sciences Summit, Panel Discussion, "The Role of the General Counsel in Risk Management: How to Create an Ethical Culture and Reduce Risk," October 2016
Moderator, Norton Rose Fulbright LLP UK & European Life Sciences Academy, Panel Discussion, "The Role of General Counsel & Compliance in Risk Management: How to Create an Ethical Culture and Reduce Risk," October 2016
Presenter, Association of Corporate Counsel "Back to School" CLE Symposium, "Managing Litigation from the Inside out: How to Ensure the Best Results for the Client," August 2016
Presenter, Norton Rose Fulbright US LLP Web Seminar, "Life Sciences Securities Litigation and Enforcement Issues," May 2016
Presenter, American Conference Institute's 10^th Advanced Forum on FCPA & Anti-Corruption for the Life Sciences Industry, "Data Privacy Issues in FCPA Investigations," April 2016
Presenter, American Health Law Association, Web Seminar, "What's New in Health Care Antitrust: Multiregional Networks, Physician Acquisitions, and Vertical Theories of Harm," March 2016
Presenter, Norton Rose Fulbright US LLP Twelfth Annual Health Law Symposium, "Current Issues in Healthcare Antitrust," January 2016
Presenter, ABA Section of Antitrust Law, Panel Discussion, "Structural and Behavioral Remedies in Pharmaceutical Mergers: EU v. US," October 2015
Presenter, Norton Rose Fulbright US LLP Minneapolis Healthcare Update, "Off-label Marketing Regulations and Enforcement: Implications of the Caronia and Amarin Rulings," October 2015
Presenter, Norton Rose Fulbright US LLP Web Seminar, "Off-label Marketing Regulations and Enforcement: Implications of the Caronia and Amarin Rulings," September 2015
Presenter, NYS Bar Association Antitrust Law Section Annual Meeting, Panel Discussion, "The Dispute Over 'Reverse Payment' Settlements in Pharmaceutical Cases: Will the Supreme Court Have a Cure?," January 2013

Memberships and activities

Board Member, International Institute for Conflict Prevention & Resolution (CPR), 2023 – Present
Board Member, ALIMA USA—The Alliance for International Medical Action, 2023 – Present
ABA Antitrust Section, 1985 – Present
Antitrust and Trade Regulation Committee, New York City Bar Association, 2015 – 2023
Executive Board, New York State Bar Association Antitrust Law Section, 2012 – 2017
Vice Chair, ABA Antitrust Section, Robinson-Patman Act Committee, 1997 – 2000
Vice Chair, ABA Antitrust Section, Sherman Act Section 2 Committee, 1994 – 1997